Overview

A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

Status:
COMPLETED

Trial end date:
2024-12-27

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the diagnostic performance of \[68Ga\]Ga-DOTA-TATE Positron Emission Tomography (PET)/Computerized Tomography (CT) imaging compared with conventional imaging (CIM) as standard of truth in patients with neuroendocrine neoplasms (NENs) and healthy volunteers (HVs). The data from this study will provide the evidence for diagnosis of \[68Ga\]Ga-DOTA-TATE PET/CT imaging in patient with NENs in Japan.

Phase:

PHASE3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Eckert & Ziegler Radiopharma GmbH